Mads Daugaard

Mads Daugaard

Company: Rakovina Therapeutics

Job title: President & Chief Scientific Officer

Seminars:

Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma 9:00 am

kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibitionRead more

day: Day One

OUR CONTACT DETAILS

T: +1 617 455 4188
E: info@hansonwade.com

ABOUT US

Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

JOIN OUR TEAM

We are always looking for ambitious people to join our team. You’ll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business.

Click here to learn about Careers

DATE

Returning 2024

SEARCH

ORGANISED BY

Terms & Conditions

Privacy Policy

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.